Company intelligence / Profile preview

Celtic Biotech

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Celtic Biotech develops novel therapies for solid cancers and pain using specialized receptor-binding proteins derived from snake venoms. Their lead candidate, CB24 (Crotoxin), has shown high cytotoxicity against various tumor cell lines—especially those with high EGFR expression—and demonstrated significant anti-tumor efficacy in preclinical models. The company has advanced to phase I human trials and received notable grant funding from the EU EIC Accelerator and other sources[2][7]. No commercial products yet; still pre-revenue.

Therapeutic areas: OncologyNeurologyNephrology
Modalities: Peptides (snake venom-derived)Protein-based therapeutics
Industry: Biotech

Drug pipeline

6 assets

crotoxin

5 more assets in the full pipeline.

Partnerships

Not explicitly listed. Collaborates with leading oncologists in France/Ireland and academic neurotoxins experts[2][7].

Beyond the preview

Go deeper on Celtic Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celtic Biotech.